The latest announcement is out from Aarti Pharmalabs Limited ( (IN:AARTIPHARM) ).
Aarti Pharmalabs Limited has announced an addendum to its Subscription and Shareholders’ Agreement with Hemant Bandodkar & family, resulting in Ganesh Polychem Limited becoming a joint venture of Aarti Pharmalabs as of March 31, 2025. This strategic move is expected to enhance Aarti Pharmalabs’ operational capabilities and market positioning, as the company will now prepare consolidated financial statements using the equity method of consolidation, potentially impacting its financial reporting and stakeholder interests.
More about Aarti Pharmalabs Limited
Aarti Pharmalabs Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. The company is known for its extensive product portfolio catering to various therapeutic segments and has a significant presence in both domestic and international markets.
YTD Price Performance: 7.38%
Average Trading Volume: 43,226
For a thorough assessment of AARTIPHARM stock, go to TipRanks’ Stock Analysis page.